CRA Financial Services LLC increased its stake in AbbVie Inc. (NYSE: ABBV – Get Rating) by 27.2% in Q1, HoldingsChannel reports. The institutional investor held 9,060 shares of the company after purchasing an additional 1,939 shares during the quarter. CRA Financial Services LLC’s holdings in AbbVie were worth $1,469,000 at the end of the most recent reporting period.

Several other hedge funds have also recently changed their holdings in ABBV. Castle Financial & Retirement Planning Associates Inc. acquired a new position in AbbVie during the fourth quarter worth approximately $25,000. Intelligent Financial Strategies acquired a new position in AbbVie during the fourth quarter worth approximately $27,000. Psagot Value Holdings Ltd. Israel increased its position in AbbVie by 311.3% during the fourth quarter. Psagot Value Holdings Ltd. Israel now owns 4,360 shares in the company valued at $28,000 after buying an additional 3,300 shares in the last quarter. Steward Financial Group LLC acquired a new position in AbbVie during the fourth quarter valued at around $30,000. Finally, Maryland Capital Advisors Inc. acquired a new position in AbbVie during the fourth quarter valued at approximately $41,000. Institutional investors and hedge funds hold 67.03% of the company’s shares.

ABBV shares opened at $152.34 on Monday. The company has a current ratio of 0.82, a quick ratio of 0.71 and a debt ratio of 3.89. The stock has a market capitalization of $269.20 billion, a P/E ratio of 21.86, a price-to-earnings growth ratio of 4.29 and a beta of 0.83. The company’s fifty-day simple moving average is $149.71 and its two-hundred-day simple moving average is $146.92. AbbVie Inc. has a 12-month low of $105.56 and a 12-month high of $175.91.

AbbVie (NYSE: ABBV – Get Rating) last released its quarterly results on Friday, April 29. The company reported EPS of $3.16 for the quarter, beating consensus analyst estimates of $3.15 by $0.01. The company posted revenue of $13.36 billion for the quarter, versus $13.61 billion expected by analysts. AbbVie had a net margin of 22.00% and a return on equity of 159.31%. The company’s quarterly revenue increased 2.7% from the same quarter last year. In the same quarter a year earlier, the company posted earnings of $2.95 per share. As a group, research analysts predict that AbbVie Inc. will post EPS of 14.02 for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, August 15. Shareholders of record on Friday, July 15 will receive a dividend of $1.41 per share. The ex-dividend date is Thursday, July 14. This represents a dividend of $5.64 on an annualized basis and a dividend yield of 3.70%. AbbVie’s dividend payout ratio (DPR) is currently 80.92%.

In other news, Executive Vice Chairman Henry O. Gosebruch sold 83,960 shares in a trade dated Monday, May 16. The shares were sold at an average price of $155.00, for a total transaction of $13,013,800.00. Following the transaction, the executive vice president now owns 16,623 shares of the company, valued at approximately $2,576,565. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available on the SEC’s website. Additionally, Vice Chairman Michael Severino sold 100,000 shares of the company in a transaction dated Friday, May 6. The stock was sold at an average price of $150.81, for a total transaction of $15,081,000.00. Following the completion of the sale, the insider now owns 152,103 shares of the company, valued at approximately $22,938,653.43. The disclosure of this sale can be found here. Insiders sold a total of 463,761 shares of the company worth $70,609,771 over the past three months. Insiders own 0.08% of the shares of the company.

Several research analysts commented on the title. Wells Fargo & Company raised its price target on AbbVie shares from $165.00 to $200.00 in a Monday, May 2 research report. SVB Leerink began covering AbbVie shares in a Monday, May 23 report. They set an “underperforming” rating and a price target of $140.00 for the company. Morgan Stanley raised its price target on AbbVie shares from $142.00 to $192.00 and gave the stock an “overweight” rating in a Wednesday, April 6 report. Daiwa Capital Markets downgraded AbbVie shares from an “outperform” rating to a “neutral” rating and set a price target of $150.00 for the company. in a report on Friday, May 6. Finally, UBS Group downgraded AbbVie shares from a “buy” rating to a “neutral” rating and raised its price target for the stock from $129.00 to $147.00 in a report from the Monday February 28. One equity research analyst has assigned the stock a sell rating, five have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating for the stock. According to MarketBeat, the stock has a consensus rating of “moderate buy” and an average price target of $159.75.

Profile AbbVie (Get an assessment)

AbbVie Inc discovers, develops, manufactures and sells pharmaceutical products worldwide. The Company offers HUMIRA, an injection therapy for autoimmune and intestinal Behçet’s disease; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1 to 6 infection.

See also

Want to see which other hedge funds own ABBV? Visit HoldingsChannel.com for the latest 13F filings and insider trading for AbbVie Inc. (NYSE:ABBV – Get Rating).

Get news and reviews for AbbVie Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for AbbVie and related companies with MarketBeat.com’s free daily email newsletter.